Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...
Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.
TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly ...
Longeveron Inc., a biotechnology company focused on regenerative medicine, has licensed a US patent from the University of Miami aimed at developing cardiomyogenic precursor cells from pluripotent ...
A woman with a failing heart has been kept alive with the help of a new "breakthrough" stem-cell technology, scientists report. The 46-year-old woman had experienced a heart attack in 2016 and ...
Parkinson's Disease Research: Parkinson's disease is a chronic neurological disorder that affects body movement. Let us tell ...
Researchers have developed a capsule-based method that makes it possible to analyze the same cell through multiple experimental steps. The technology overcomes a long-standing limitation in cell ...
MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric ...
Leading the commercialization of space-age cellular science for personal care products, Naples Soap Company set to the launch nationally a new personal care product line utilizing NASA’s 3D biometric ...
How does a tiny cluster of cells become an embryo with a head, trunk, and tail? And how do thousands of genes coordinate this development? A new imaging method makes it possible to visualize the ...
İSTANBUL, Türkiye, April 7, 2025 (EZ Newswire) -- Renowned hair transplant specialist Dr. Serkan Aygin, awarded “Best Hair Transplant Doctor in Europe” in 2019 by a Paris medical committee, has today ...